Atlas FDA

SUPARTZ FX

FDA premarket approval P980044/S025 · decided 2015-05-20

Approval details

PMA number
P980044
Supplement
S025
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
SUPARTZ FX
Generic name
Acid, hyaluronic, intraarticular
Applicant
Seikagaku Corp.
Date received
2015-04-07
Decision date
2015-05-20
Days to decision
43 days
Decision code
APPR
Product code
MOZ
Advisory committee
Orthopedic
Expedited review
No
Location
Tokyo
Statement
APPROVAL FOR A CHANGE OF THE TRADE NAME OF YOUR DEVICE FROM SUPARTZ TO SUPARTZ FX. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME SUPARTZ FX AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE, NON-PHARMACOLOGIC THERAPY AND SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
HADGEL, 4 GRAM/SYRINGE (K011544)Seikagaku Corp.2001-08-15